New Technologies, New Vaccines 2016

Agenda

Sunday, March 20

All events located in Christiana Room

5:00 p.m.—6:30 p.m.
Registration Opens
6:00 p.m.
Welcome Reception

Day 1 — Monday, March 21

All sessions located in King-Sullivan Room, Mezzanine level

8:00 a.m.—6:00 p.m.
Vendor Show by Scientist Solutions, King-Sullivan Lobby
8:30 a.m.
Continental Breakfast
9:00 a.m.
Welcome – Dr. Vidadi Yusibov
9:05 a.m.
Keynote Address – Dr. Gregory Poland, Director of Vaccine Research, The Mayo Clinic “Vaccinology 3.0: An Evolving Paradigm in the 21st Century
Networking

Note: All session talks are 20 minutes each and each session chair gets 10 minutes to introduce the session.

10:30 a.m. — 12:00 p.m.
SESSION 1: CHALLENGES AND SOLUTIONS IN VACCINE DISCOVERY: TARGET VALIDATION
Dr. Paula Bryant Ph.D., (Session Chair), Senior Scientific Officer, NIH/NIAID/DMID/OBRRTR
Janice M. Moser, Ph.D., Director of Immunological Research, Sanofi Pasteur, “In vitro MIMIC® human immune evaluations: from the cradle to the grave”
Remi Villenave, Ph.D., Emulate, “Organs-on-Chips applied to infectious diseases and vaccines development”
Bradley R. Ringeisen, Head of Biofabrication Section, U.S. Naval Research Laboratory, “3D Bioprinting and Biopaper Technologies for Creating High Throughput In Vitro Tissue Assays”
Omar Khan, Ph.D., Postdoctoral Associate, Massachusetts Institute of Technology, “Rapid Intervention vaccine platform technologies created through engineering design criteria”
Lunch & Networking
1:00 p.m. — 2:30 p.m.
SESSION 2: CALLENGES AND SOLUTIONS IN VACCINE DISCOVERY: NOVEL TARGET EXPRESSION SYSTEMS
Mannon Cox, Ph.D., (Session Chair), President & CEO, Protein Sciences
Mannon Cox, Ph.D., President & CEO, Protein Sciences, “Challenges and Solution in Vaccine Discovery: Overview of target expression systems”
Henry Daniell, Ph.D., Professor, University of Pennsylvania, “Vaccination through chloroplast genetics: Affordable protein drugs for the prevention and treatment of human diseases”
Steve Chappell, Ph.D., Scientific Director, Promosome, “Engineering mRNAs for increased protein expression and safety in bioreactors and patients”
Wian deJongh, Ph.D., CSO & Co-Founder, Expres2ion Biotechnologies, Denmark, “Development of Drosophila S2 based sub-unit antigen vaccine production processes”
Networking
3:00 p.m. — 4:50 p.m.
SESSION 3: CHALLENGES AND SOLUTIONS IN VACCINE DISCOVERY: APPLICATIONS OF GENOMIC TECHNOLOGIES
Dr. Richard Kennedy, (Session Chair), Professor, The Mayo Clinic
Dr. Richard Kennedy, Professor, The Mayo Clinic, “Human immunogenomics”
Jean Luc Bodmer, Ph.D., Director, Genocea Biosciences, “Parsing the T Cell Immune Response Repertoire: Mining Proteomes for Antigenic Gems”
John Tsang, Ph.D., Chief, Systems Genomics and Bioinformatics Unit, NIH/NIAID, “Utilizing population variation and systems biology to study vaccination responses in humans”
Inna Ovsyannikova, Ph.D., Professor, The Mayo Clinic College of Medicine, “The Role of Immunogenetics in Vaccine Development”
Lenny Moise, Ph.D., Scientific Director, Vaccine Research, EpiVax, “Higher H7N9 Vaccine Immunogenicity Engineered by Regulatory T Cell Epitope Deletion”
4:50 p.m. — 6:00 p.m.
Vendor Show, Reception — King-Sullivan Lobby
6:00 p.m. — 8:00 p.m.
Conference Dinner — Gold Ballroom
Mr. Bernard Rudnick, Cap Genic Advisors, “The promise of plasmid-based vaccines.

Day 2 — Tuesday, March 22

All sessions located in King-Sullivan Room, Mezzanine level

8:00 a.m.
Continental Breakfast
8:30 a.m.
Plenary talk – Dr. Santosh Nanda, USFDA, “Regulatory landscape for new vaccine technologies”

Note: All session talks are 20 minutes each and each session chair gets 10 minutes to introduce the session.

9:00 a.m. — 10:50 a.m.
SESSION 4: VACCINE DEVELOPMENT: ADJUVANTS
Dr. Carl R. Alving, (Session Chair), Chief, Laboratory of Adjuvants & Antigen Research, Walter Reed Army Institute of Research
Dr. Carl R. Alving, Chief, Laboratory of Adjuvants & Antigen Research, Walter Reed Army Institute of Research, “Adjuvants for Human Vaccines”
Ali Fattom, Ph.D., Sr. Vice President, NanoBio, “Mucosal Immunity induced by nanoemulsion-adjuvant intranasal vaccines may be useful in preventing infections and carriage of mucosal pathogens”
Andrew Bett, Ph.D., Sr. Principal Scientist, Merck, “Cationic Lipid Nanoparticles Significantly Boosts B-cell and T-cell Responses to a Tetravalent Dengue Virus Vaccine”
Yvonne Perrie, Ph.D., Professor, Aston University, “Developing cationic liposomes as vaccine adjuvants”
David Lanar, Ph.D., Walter Reed Army Institute of Research, USAMRMC “The use of Army Liposomal Formulation (ALF) adjuvants with Self-Assembling Protein Nanoparticles (SAPN) to induce anti-malaria protective responses to the Plasmodium falciparum circumsporozoite protein”
Networking
11:10 a.m. — 12:40 p.m.
SESSION 5: VACCINE DEVELOPMENT: STABILITY & DELIVERY
Dr. Murali Bilikallahalli, (Session Chair), Associate Director, MedImmune
Dr. Murali Bilikallahalli, Associate Director, MedImmune, “Formulation challenges in developing nucleic based vaccine drug products: Adjuvants & Expression Systems”
Tudor Arvinte, Ph.D., CEO, Therapeomic, “Aggregation of Biotherapeutics in Human Plasma Depends on the Structure of the Molecule and on Formulation”
Mark Jones, Ph.D., Sr. Scientist, Fraunhofer Center for Molecular Biotechnology, “Stability and Preformulation Development of a Plant-produced Anthrax Vaccine Candidate”
John Hickey, Ph.D., Sr. Research Scientist, University of Kansas, “Analytical Characterization and Preformulation Development Studies of a Recombinant Double Mutant Heat Labile Toxin (dmLT)”
Lunch & Networking
1:40 p.m. — 3:10 p.m.
SESSION 6: VACCINE DEVELOPMENT: POTENCY ASSAYS
Dr. William Egan, (Session Chair), Director, GlaxoSmithKline
Dr. William Egan, (Session Chair), Director, GlaxoSmithKline, “An Overview of Potency Assay for Vaccines: Yesterday and Today”
Robin Levis, Ph.D., Deputy Director, Division of Vaccine Res. & Review, USFDA, “Critical Regulatory Aspects for Vaccine Potency Test Development”
Christine C. Roberts, Ph.D., Director of Clinical Laboratory Development, GeneOne Life Sciences, “Emerging Infections: Vaccine Clinical Assay Challenges”
Jeremiah Trausch, Ph.D., Post Doctorate, Merck, “Using DNA aptamers to improve vaccine potency assays”
Networking
3:30 p.m. — 5:00 p.m.
SESSION 7: THERAPEUTIC MONOCLONAL ANTIBODY
Dr. Alex Therien, (Session Chair), Director, Merck
Dr. Alex Therien, Director, Merck, “Passive immunization with antitoxin antibodies for the prevention of C. difficile infection”
Scott Dessain, Ph.D., Associate Professor, Lankenau Institute for Medical Research, “Can Human Monoclonal Antibodies Contribute to the Global Polio Eradication Initiative?”
Marjorie A. Shapiro, Ph.D., Chief, Lab of Mol. & Developmental Immunology OBP/OPQ/CDER/FDA, “Regulatory Considerations for the Development of Monoclonal Antibodies and Antibody Cocktails”
Brian Haines, Ph.D., Principal Scientist, Merck, “Preclinical Strategies to Support the Oncology Clinical Development of the Anti-PD-1 Antibody Pembrolizumab/Keytruda”
5:00 p.m. — 7:00 p.m.
Poster Session, King-Sullivan Lobby
7:00 p.m.
Speaker Dinner, Christiana Room

Free night for attendees

Day 3 — Wednesday, March 23

All sessions located in King-Sullivan Room, Mezzanine level

8:00 a.m.
Continental Breakfast
8:30 a.m.
Plenary talk- Marcos da Silva Freire, Ph.D., BioManguinhos/FIOCRUZ, Brazil, “Zika

Note: All session talks are 20 minutes each and each session chair gets 10 minutes to introduce the session.

9:00 a.m. — 10:30 a.m.
SESSION 8: EMERGING AND RE-EMERGING INFECTIOUS DISEASES
Stanley Plotkin, M.D., (Session Chair), Emeritus Professor of Pediatrics, University of Pennsylvania
Stanley Plotkin, M.D., Emeritus Professor of Pediatrics, University of Pennsylvania, “The History and Future of Lyme Disease Vaccines”
Clifford Lane, Director, Division of Clinical Research, NIH/NIAID, “Ebola: Lessons learned”
Dr. David Weiner, Professor, University of Pennsylvania, “MERS; what we have learned”
Joel Maslow, M.D., Ph.D., M.B.A., Chief Medical Officer, GeneOne Life Sciences, “Study design considerations for DNA vaccines against emergent infectious diseases”
Networking
11:00 a.m. — 12:30 p.m.
SESSION 9: MOSQUITO TRANSMITTED INFECTIOUS DISEASES
Kathryn Zoon, (Session Chair), NIH
Steve Whitehead, NIH/NIAID, “Dengue Vaccines: How close are we?”
Leonard Friedland, GSK, “RTS.S-the journey towards a malaria vaccine”
Dr. Wataru Akahata, CEO, VLP Therapeutics, “Development of a Malaria Vaccine using an Alphavirus Virus-Like Particle (i-aVLP) Platform”
Steve Whitehead, NIH/NIAID, “Zika”
Conference Adjourns